Values Of Urinary β2-mini-globulin Assay In Predicting Of Patients With Primary Membranous Nephropathy And Its Clinical Significance

[Objective] To address the value of urinary β2-miniglobulin (β 2-MG) detection in patients with primary membranous nephropathy and its clinical significance. [Methods] 20 cases of primary membranous nephropathy with nephritic syndrome diagnosed by renal biopsy were randomly selected and the content of urinary β2-MG was detected by radial immunoassay. According to the detected content of urinary β2-MG, it was divided into two groups of group A( β2-MG > 0.3μg/ml) and group B (β2-MG 0.3μg/ml). The group A and B was randomly divided into two subgroups of control group treated with prednisone and treatment group treated with prednisone and cyclophosphamide (CTX), respectively. [Results] The content of urinary β2-MG in the patients with primary membranous nephropathy was positively correlated to the severity of this disease, namely, the more high content of the urinary β2-MG, the more serious state of this disease. The exacerbation ratio of renal function in group A was significantly higher than that in group B (P<0.001), and therefore patients in group A might be considered as the individuals of high risk, while patients in group B as recovering persons. The cure rate of treatment group in group A was significantly higher than that of control group (P<0.05) andthe occurrence rate of side effects had no significant difference between the two subgroups (P>0.05). The cure rate had no difference between two subgroups in group B (P>0.05), but the recover time of patients in treatment group was obviously shorter than that in control group (P<0.05), and the occurrence rate of side effects in treatment group was significantly higher than that in control group (P<0.05). [Conclusions] The content of the urinary β2-MG could be used for as a valuable index in predicting for the primary membranous nephropathy and it is useful to find out the potential interstitial lesions of renal tubules that might be not found out by renal biopsy. The patients with high risk are treated with immuno-inhibitor in early stage to improve the therapeutic effects. The patients in recovering states are not needed to misuse the immuno-inhibitor to avoid the side effects that is also economic and effective for treatment.